Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

<p>Background: The conversion therapy for advanced hepatocellular carcinoma (HCC) shows promise with a triple therapy approach that combines interventional therapy, immune checkpoint inhibitors, and molecular targeted therapy (primarily small-molecule TKIs and the large-molecule bevacizum...

Full description

Bibliographic Details

Main Authors:	Zhaolong Pan, Dongming Liu, Junbo Cao, Linlin Fu, Xihao Zhang, Xiaodong Zhu, Yangxun Pan, Jianwei Liu, Chuangye Han, Renan Jin, Shunli Shen, Xiaoyun Zhang, Hongzhi Liu, Xiaobo Yang, Kuan Hu, Xiaoyi Shi, Dongxu Wang, Yang Zhao, Jianhong Zhong, Bangde Xiang, Shanzhi Gu, Tao Li, Shuijun Zhang, Ledu Zhou, Haitao Zhao, Yongyi Zeng, Tianfu Wen, Ming Kuang, Xiao Liang, Tao Peng, Kui Wang, Li Xu, Huikai Li, Tianqiang Song, Huichuan Sun, Wei Zhang
Format:	Artigo
Language:	Inglês
Published:	Karger Publishers 2025-01-01
Series:	Liver Cancer
Online Access:	https://karger.com/article/doi/10.1159/000545545
Tags:	Add Tag No Tags, Be the first to tag this record!